UNLABELLED: We have previously shown that the microenvironment of human embryonic stem cells (hESCs) is able to change and reprogram aggressive cancer cells to a less aggressive state. Some mechanisms implicated in the phenotypic changes observed after this exposure are mainly associated with the Nodal signaling pathway, which plays a key role in tumor cell plasticity. However, several other molecular mechanisms might be related directly and/or indirectly to these changes, including microRNA (miRNA) regulation and DNA methylation. AIM: To further explore the epigenetic mechanisms potentially underlying the phenotypic changes that occur after exposing metastatic melanoma cells to a hESC microenvironment. MATERIALS & METHODS: A total of 365 miRNAs were screened using the TaqMan® Low Density Arrays. We also evaluated whether DNA methylation could be one of the factors regulating the expression of the inhibitor of Nodal, Lefty, in hESCs (where it is highly expressed) vs melanoma cells (where it is not expressed). RESULTS: Using these experimental approaches, we identified miRNAs that are up- and down-regulated in melanoma cells exposed to a hESC microenvironment, such as miR-302a and miR-27b, respectively. We also demonstrate that Notch4 is one of the targets of miR-302a, which is upstream of Nodal. Additionally, one of the mechanisms that might explain the absence of the inhibitor of Nodal, Lefty, in cancer cells is silencing by DNA methylation, which provides new insights into the unregulated expression of Nodal in melanoma. CONCLUSION: These findings suggest that epigenetic changes such as DNA methylation and regulation by microRNAs might play a significant role in tumor cell plasticity and the metastatic phenotype.
UNLABELLED: We have previously shown that the microenvironment of human embryonic stem cells (hESCs) is able to change and reprogram aggressive cancer cells to a less aggressive state. Some mechanisms implicated in the phenotypic changes observed after this exposure are mainly associated with the Nodal signaling pathway, which plays a key role in tumor cell plasticity. However, several other molecular mechanisms might be related directly and/or indirectly to these changes, including microRNA (miRNA) regulation and DNA methylation. AIM: To further explore the epigenetic mechanisms potentially underlying the phenotypic changes that occur after exposing metastatic melanoma cells to a hESC microenvironment. MATERIALS & METHODS: A total of 365 miRNAs were screened using the TaqMan® Low Density Arrays. We also evaluated whether DNA methylation could be one of the factors regulating the expression of the inhibitor of Nodal, Lefty, in hESCs (where it is highly expressed) vs melanoma cells (where it is not expressed). RESULTS: Using these experimental approaches, we identified miRNAs that are up- and down-regulated in melanoma cells exposed to a hESC microenvironment, such as miR-302a and miR-27b, respectively. We also demonstrate that Notch4 is one of the targets of miR-302a, which is upstream of Nodal. Additionally, one of the mechanisms that might explain the absence of the inhibitor of Nodal, Lefty, in cancer cells is silencing by DNA methylation, which provides new insights into the unregulated expression of Nodal in melanoma. CONCLUSION: These findings suggest that epigenetic changes such as DNA methylation and regulation by microRNAs might play a significant role in tumor cell plasticity and the metastatic phenotype.
Entities:
Keywords:
DNA methylation; Lefty; Nodal; Notch; hESC microenvironment; microRNAs
Authors: Junji Morokuma; Douglas Blackiston; Dany S Adams; Guiscard Seebohm; Barry Trimmer; Michael Levin Journal: Proc Natl Acad Sci U S A Date: 2008-10-17 Impact factor: 11.205
Authors: Lynne-Marie Postovit; Fabricio F Costa; Jared M Bischof; Elisabeth A Seftor; Bo Wen; Richard E B Seftor; Andrew P Feinberg; Marcelo Bento Soares; Mary J C Hendrix Journal: J Cell Biochem Date: 2007-07-01 Impact factor: 4.429
Authors: Lynne-Marie Postovit; Elisabeth A Seftor; Richard E B Seftor; Mary J C Hendrix Journal: Expert Opin Ther Targets Date: 2007-04 Impact factor: 6.902
Authors: C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: Luigi Strizzi; Lynne-Marie Postovit; Naira V Margaryan; Alina Lipavsky; Jules Gadiot; Christian Blank; Richard Eb Seftor; Elisabeth A Seftor; Mary Jc Hendrix Journal: Expert Rev Dermatol Date: 2009
Authors: Philip Lui; Richard Cashin; Márcio Machado; Michiel Hemels; Patricia K Corey-Lisle; Thomas R Einarson Journal: Cancer Treat Rev Date: 2007-10-04 Impact factor: 12.111
Authors: Luigi Strizzi; Katharine M Hardy; Dawn A Kirschmann; Lars Ahrlund-Richter; Mary J C Hendrix Journal: Cancer Res Date: 2012-04-15 Impact factor: 12.701
Authors: Elisabeth A Seftor; Richard E B Seftor; Don Weldon; Gina T Kirsammer; Naira V Margaryan; Alina Gilgur; Mary J C Hendrix Journal: Semin Oncol Date: 2014-02-07 Impact factor: 4.929
Authors: Sergey Malchenko; Vasiliy Galat; Elisabeth A Seftor; Elio F Vanin; Fabricio F Costa; Richard E B Seftor; Marcelo B Soares; Mary J C Hendrix Journal: J Cell Physiol Date: 2010-11 Impact factor: 6.384
Authors: James C Garbe; Francois Pepin; Fanny A Pelissier; Klara Sputova; Agla J Fridriksdottir; Diana E Guo; Rene Villadsen; Morag Park; Ole W Petersen; Alexander D Borowsky; Martha R Stampfer; Mark A Labarge Journal: Cancer Res Date: 2012-05-02 Impact factor: 12.701
Authors: Zhila Khalkhali-Ellis; Vasiliy Galat; Yekaterina Galat; Alina Gilgur; Elisabeth A Seftor; Mary J C Hendrix Journal: Stem Cells Dev Date: 2016-09-19 Impact factor: 3.272
Authors: Katharine M Hardy; Luigi Strizzi; Naira V Margaryan; Kanika Gupta; George F Murphy; Richard A Scolyer; Mary J C Hendrix Journal: Mol Cancer Res Date: 2015-03-12 Impact factor: 5.852
Authors: Thomas M Bodenstine; Grace S Chandler; Richard E B Seftor; Elisabeth A Seftor; Mary J C Hendrix Journal: Cancer Metastasis Rev Date: 2016-03 Impact factor: 9.264
Authors: Mary J C Hendrix; Elisabeth A Seftor; Richard E B Seftor; Jun-Tzu Chao; Du-Shieng Chien; Yi-Wen Chu Journal: Pharmacol Ther Date: 2016-01-22 Impact factor: 12.310